Literature DB >> 22302086

An explorative analysis of secretory receptor for advanced glycation endproducts in primary focal segmental glomerulosclerosis.

Harin Rhee1, Sang Heon Song, Ihm Soo Kwak, Il Young Kim, Eun Young Seong, Dong Won Lee, Soo Bong Lee.   

Abstract

BACKGROUND: Despite remarkable medical progress, the main pathogenetic mechanisms of focal segmental glomerulosclerosis (FSGS) have not been fully delineated and its prognosis is poor at present. Recently, it was revealed that the receptor for advanced glycation endproducts (RAGE) was highly expressed at the base of podocytes with an up-regulation mainly in diabetic nephropathy. However, there is no report about the association between glomerulonephritis and RAGE. The aims of the current study were to explore the relationships between several clinical parameters and circulating soluble RAGE in primary FSGS and compare serum levels in primary FSGS with immunoglobulin A nephropathy (IgAN) and controls.
METHODS: A total of 35 subjects aged >18 years were enrolled. Thirty-five subjects consisted of three groups: primary FSGS (N = 15), IgAN (N = 10), and normal controls (N = 10). Laboratory measurements of serum carboxymethyl-lysin (CML), soluble RAGE (sRAGE), and endogenous secretory RAGE (esRAGE) were performed.
RESULTS: Serum esRAGE level in the FSGS group was higher than that in the IgAN group (0.55 ± 0.32 ng/mL vs. 0.27 ± 0.11 ng/mL, p = 0.013). There was no statistical difference between sRAGE and CML among the three groups. Within the FSGS group, esRAGE, but not sRAGE, was positively correlated with 24-h urinary protein (r = 0.553, p = 0.033) and negatively correlated with body mass index (r = -0.623, p = 0.013). In stepwise multiple regression analysis, body mass index and 24-h urinary protein were significant contributors to esRAGE within the FSGS group.
CONCLUSION: This study showed that only the serum level of esRAGE, not sRAGE, was higher in the FSGS group than in the IgAN and control groups. The amount of 24-h proteinuria was also related to the serum level of esRAGE in the FSGS group.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22302086     DOI: 10.1007/s10157-012-0599-1

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  29 in total

1.  Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses.

Authors:  Giuseppina Basta; Guido Lazzerini; Marika Massaro; Tommaso Simoncini; Piero Tanganelli; Caifeng Fu; Thomas Kislinger; David M Stern; Ann Marie Schmidt; Raffaele De Caterina
Journal:  Circulation       Date:  2002-02-19       Impact factor: 29.690

2.  N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins.

Authors:  S Reddy; J Bichler; K J Wells-Knecht; S R Thorpe; J W Baynes
Journal:  Biochemistry       Date:  1995-08-29       Impact factor: 3.162

3.  Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.

Authors:  K C B Tan; S W M Shiu; W S Chow; L Leng; R Bucala; D J Betteridge
Journal:  Diabetologia       Date:  2006-09-13       Impact factor: 10.122

Review 4.  Trends in the epidemiology of focal segmental glomerulosclerosis.

Authors:  Chagriya Kitiyakara; Jeffrey B Kopp; Paul Eggers
Journal:  Semin Nephrol       Date:  2003-03       Impact factor: 5.299

Review 5.  Current status of dialysis therapy in Korea.

Authors:  Dong Chan Jin
Journal:  Korean J Intern Med       Date:  2011-06-01       Impact factor: 2.884

6.  Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications.

Authors:  Naoto Katakami; Munehide Matsuhisa; Hideaki Kaneto; Taka-Aki Matsuoka; Ken'ya Sakamoto; Yoshihisa Nakatani; Kentaro Ohtoshi; Rieko Hayaishi-Okano; Keisuke Kosugi; Masatsugu Hori; Yoshimitsu Yamasaki
Journal:  Diabetes Care       Date:  2005-11       Impact factor: 19.112

7.  Racial differences in trends of end-stage renal disease, by primary diagnosis--United States, 1994-2004.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2007-03-23       Impact factor: 17.586

8.  Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease.

Authors:  Nozomu Tanji; Glen S Markowitz; Caifeng Fu; Thomas Kislinger; Akihiko Taguchi; Monika Pischetsrieder; David Stern; Ann Marie Schmidt; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2000-09       Impact factor: 10.121

Review 9.  Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury.

Authors:  Hideto Yonekura; Yasuhiko Yamamoto; Shigeru Sakurai; Takuo Watanabe; Hiroshi Yamamoto
Journal:  J Pharmacol Sci       Date:  2005-03-05       Impact factor: 3.337

10.  Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes.

Authors:  A M Schmidt; O Hori; J X Chen; J F Li; J Crandall; J Zhang; R Cao; S D Yan; J Brett; D Stern
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

View more
  2 in total

1.  AGEs-RAGE overexpression in a patient with smoking-related idiopathic nodular glomerulosclerosis.

Authors:  Nao Nakamura; Kensei Taguchi; Yoshihiro Miyazono; Keiichiro Uemura; Kiyomi Koike; Yuka Kurokawa; Yosuke Nakayama; Yusuke Kaida; Ryo Shibata; Akihiro Tsuchimoto; Katsuhiko Asanuma; Kei Fukami
Journal:  CEN Case Rep       Date:  2017-11-27

2.  Decoding the Mechanism behind the Pathogenesis of the Focal Segmental Glomerulosclerosis.

Authors:  Xiao Zhu; Liping Tang; Jingxin Mao; Yasir Hameed; Jingyu Zhang; Ning Li; Danny Wu; Yongmei Huang; Chen Li
Journal:  Comput Math Methods Med       Date:  2022-04-19       Impact factor: 2.809

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.